On September 7, 2023, Cerba HealthCare, a global leader in medical diagnostics, acquired CIRION BioPharma Research Inc., a Canadian contract research organization known for bioanalytical and global central laboratory services. CIRION, operational for over 30 years, specializes in biosimilars/biologics development and supports international multi-center clinical studies with over 80 employees, including PhD holders and medical specialists.

Cerba HealthCare values CIRION’s expertise in large molecules development and high-quality services, compliant with GLP standards and accredited by CAP and CLIA. CIRION’s client base includes top global pharmaceutical companies, reflecting its reputation in the industry.

CIRION offers comprehensive services from assay development to laboratory testing for clinical studies, meeting the complex needs of its clients. The company also provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Under Cerba HealthCare’s Cerba Research brand, the acquisition enhances their clinical laboratory and diagnostic solutions for clinical and IVD trials. Cerba Research has a strong track record in patient recruitment, clinical trial sample testing, and logistics solutions for various medical fields, including immuno-oncology and cell & gene therapies. This acquisition supports Cerba’s position as a precision medicine partner to CROs, biotech, and pharmaceutical industries.